The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling

Nature Communications

Volumn 3, Issue , 2012, Pages

  Bock, Andreas ^a   Merten, Nicole ^a   Schrage, Ramona ^a   Dallanoce, Clelia ^c   Bätz, Julia ^c   Klöckner, Jessica ^c   Schmitz, Jens ^b   Matera, Carlo ^a   Simon, Katharina ^a   Kebig, Anna ^a   Peters, Lucas ^a   Müller, Anke ^a   Schrobang Ley, Jasmin ^a   Tränkle, Christian ^a   Hoffmann, Carsten ^c   De Amici, Marco ^b   Holzgrabe, Ulrike ^c   Kostenis, Evi ^a   Mohr, Klaus ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; MUSCARINIC M2 RECEPTOR; PILOCARPINE; RECEPTOR; TRANSMEMBRANE HELICAL RECEPTOR; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL STRAIN HEK293; CHO CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIGAND BINDING; NONHUMAN; PROTEIN CONFORMATION; RECEPTOR BINDING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ALLOSTERIC SITE; GTP-BINDING PROTEINS; HUMANS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, MUSCARINIC M2; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84867010308     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms2028     Document Type: Article

References (55)

1. Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nat. Rev. Drug Discov. 5, 993-996 (2006). (Pubitemid 44835126)
2. Lagerstrom, M. C. & Schioth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7, 339-357 (2008).
3. DeWire, S. M., Ahn, S., Lefkowitz, R. J. & Shenoy, S. K. β-Arrestins and cell signaling. Annu. Rev. Physiol. 69, 483-510 (2007).
4. Simon, M. I., Strathmann, M. P. & Gautam, N. Diversity of G proteins in signal transduction. Science 252, 802-808 (1991). (Pubitemid 121000516)
5. Kenakin, T. & Miller, L. J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265-304 (2010).
6. Rajagopal, S., Rajagopal, K. & Lefkowitz, R. J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386 (2010).
7. Smith, N. J., Bennett, K. A. & Milligan, G. When simple agonism is not enough: emerging modalities of GPCR ligands. Signalling and regulation of G protein coupled receptors. Mol. Cell. Endocrinol. 331, 241-247 (2011).
8. Deupi, X. & Kobilka, B. K. Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology (Bethesda) 25, 293-303 (2010).
9. Scheerer, P. et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 455, 497-502 (2008).
10. Rasmussen, S. G. F. et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor. Nature 469, 175-180 (2011).
11. Lebon, G. et al. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474, 521-525 (2011).
12. Reiter, E., Ahn, S., Shukla, A. K. & Lefkowitz, R. J. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 52, 179-197 (2012).
13. Rasmussen, S. G. F. et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).
14. Oldham, W. M. & Hamm, H. E. Heterotrimeric G protein activation by G-protein-coupled receptors. Nat. Rev. Mol. Cell. Biol. 9, 60-71 (2008).
15. Bokoch, M. P. et al. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 463, 108-112 (2010).
16. Christopoulos, A. & Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323-374 (2002). (Pubitemid 34575719)
17. Wess, J., Eglen, R. M. & Gautam, D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat. Rev. Drug Discov. 6, 721-733 (2007). (Pubitemid 47342315)
18. Lüllmann, H., Ohnesorge, F. K., Schauwecker, G. C. & Wassermann, O. R. Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. Eur. J. Pharmacol. 6, 241-247 (1969).
19. Stockton, J. M., Birdsall, N. J., Burgen, A. S. & Hulme, E. C. Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol. 23, 551-557 (1982).
20. Tränkle, C. et al. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Mol. Pharmacol. 64, 180-190 (2003). (Pubitemid 36759830)
21. Voigtländer, U. et al. Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol. Pharmacol. 64, 21-31 (2003). (Pubitemid 36759814)
22. Huang, X.-P., Prilla, S., Mohr, K. & Ellis, J. Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3- phthalimidopropyl)ammonium]dibromide. Mol. Pharmacol. 68, 769-778 (2005). (Pubitemid 41206031)
23. Prilla, S., Schrobang, J., Ellis, J., Höltje, H.-D. & Mohr, K. Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2 422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol. Pharmacol. 70, 181-193 (2006).
24. Antony, J. et al. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J. 23, 442-450 (2009).
25. Haga, K. et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547-551 (2012).
26. Hulme, E. C., Lu, Z. L. & Bee, M. S. Scanning mutagenesis studies of the M1 muscarinic acetylcholine receptor. Receptors Channels 9, 215-228 (2003). (Pubitemid 37069444)
27. Shi, L. & Javitch, J. A. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 42, 437-467 (2002). (Pubitemid 34162546)
28. Kloeckner, J., Schmitz, J. & Holzgrabe, U. Convergent, short synthesis of the muscarinic superagonist iperoxo. Tetrahedron Lett. 51, 3470-3472 (2010).
29. Jäger, D. et al. Allosteric small molecules unveil a role of an extracellular E2/transmembrane helix 7 junction for G protein-coupled receptor activation. J. Biol. Chem. 282, 34968-34976 (2007). (Pubitemid 350232478)
30. Haga, K. et al. Functional reconstitution of purified muscarinic receptors and inhibitory guanine nucleotide regulatory protein. Nature 316, 731-733 (1985). (Pubitemid 16239349)
31. Michal, P., Lysíková, M. & Tuc?ek, S. Dual effects of muscarinic M(2) acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists. Br. J. Pharmacol. 132, 1217-1228 (2001). (Pubitemid 32234705)
32. Schröder, R. et al. Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat. Biotech. 28, 943-949 (2010).
33. Schröder, R. et al. Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat. Protoc. 6, 1748-1760 (2011).
34. Lazareno, S. & Birdsall, N. J. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 48, 362-378 (1995).
35. Milligan, G. Principles: extending the utility of [35S]GTPγS binding assays. Trends Pharmacol. Sci. 24, 87-90 (2003). (Pubitemid 36135882)
36. Gregory, K. J., Hall, N. E., Tobin, A. B., Sexton, P. M. & Christopoulos, A. Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J. Biol. Chem. 285, 7459-7474 (2010).
37. Black, J. W. & Leff, P. Operational models of pharmacological agonism. Proc. R. Soc. Lond. B. Biol. Sci. 220, 141-162 (1983). (Pubitemid 14217337)
38. Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A. & Novick, S. A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3, 193-203 (2012).
39. Galandrin, S., Oligny-Longpré, G. & Bouvier, M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol. Sci. 28, 423-430 (2007). (Pubitemid 47087968)
40. Kenakin, T. Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol. Sci. 28, 407-415 (2007). (Pubitemid 47087972)
41. Maier-Peuschel, M. et al. A fluorescence resonance energy transfer-based M2 muscarinic receptor sensor reveals rapid kinetics of allosteric modulation. J. Biol. Chem. 285, 8793-8800 (2010).
42. Hoffmann, C. et al. A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat. Meth. 2, 171-176 (2005). (Pubitemid 41122123)
43. Hoffmann, C. et al. Fluorescent labeling of tetracysteine-tagged proteins in intact cells. Nat. Protoc. 5, 1666-1677 (2010).
44. Vilardaga, J.-P., Bünemann, M., Krasel, C., Castro, M. & Lohse, M. J. Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat. Biotech. 21, 807-812 (2003). (Pubitemid 36791401)
45. Gales, C. et al. Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat. Struct. Mol. Biol. 13, 778-786 (2006). (Pubitemid 44338771)
46. Crespo, P., Xu, N., Simonds, W. F. & Gutkind, J. S. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature 369, 418-420 (1994). (Pubitemid 24184058)
47. Lopez-Ilasaca, M., Crespo, P., Pellici, P. G., Gutkind, J. S. & Wetzker, R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase γ. Science 275, 394-397 (1997). (Pubitemid 27051618)
48. Valant, C. et al. A novel mechanism of G protein-coupled receptor functional selectivity. J. Biol. Chem. 283, 29312-29321 (2008).
49. Peeters, M. C., van Westen, G. J. P., Li, Q. & IJzerman, A. P. Importance of the extracellular loops in G protein-coupled receptors for ligand recognition and receptor activation. Trends Pharmacol. Sci. 32, 35-42 (2011).
50. Dror, R. O. et al. Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc. Natl Acad. Sci. USA 108, 13118-13123 (2011).
51. González, A., Perez-Acle, T., Pardo, L. & Deupi, X. Molecular basis of ligand dissociation in β-adrenergic receptors. PLoS ONE 6, e23815 (2011).
52. Valant, C., Robert Lane, J., Sexton, P. M. & Christopoulos, A. The best of both worlds? Bitopic orthosteric/allosteric ligands of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 52, 153-178 (2012).
53. Hilf, G. & Jakobs, K. H. Agonist-independent inhibition of G protein activation by muscarinic acetylcholine receptor antagonists in cardiac membranes. Eur. J. Pharmacol. 225, 245-252 (1992).
54. Schröder, R. et al. The C-terminal tail of CRTH2 is a key molecular determinant that constrains Gαi and downstream signaling cascade activation. J. Biol. Chem. 284, 1324-1336 (2009).
55. May, L. T., Leach, K., Sexton, P. M. & Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47, 1-51 (2007). (Pubitemid 46277033)